

Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

NCT07281781

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	University of California, Irvine
Enrollment	10 participants

Key Eligibility Criteria

Inclusion (9)

- e18years of age
 - Have a diagnosis of myelofibrosis (MF) according to the 2016 WHO criteria
 - Has a hemoglobin d 10gm/dL at screening
 - Serum ferritin e 100
 - May continue on current MPN treatment, including aspirin, hydroxyurea, interferon-alpha, ruxolitinib, fedratinib, or anagrelide.
- ... and 4 more (see full listing online)

Exclusion (13)

- Eastern Cooperative Oncology Group (ECOG) questionnaire score of e3
 - Currently pregnant or planning on being pregnant within the study period.
 - Currently taking Momelotinib or Pacritinib (these agents are purported to reduce hepcidin).
 - Currently taking any of the contraindicated medications to Nelfinavir listed in section 13.2
 - Currently breastfeeding.
- ... and 8 more (see full listing online)

Locations (1 total)

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States